SUZANNE SAVAGE: Open Payments
NPI 1316219165 · NORTH KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$611 in 34 payments from 17 companies in 2025. Trend: 2023 $894 · 2024 $639 · 2025 $611
Food & beverage: $611
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 5 | $79 |
| Astellas Pharma US Inc | 3 | $67 |
| ABBVIE INC. | 3 | $63 |
| Amgen Inc. | 4 | $62 |
| GlaxoSmithKline, LLC. | 3 | $58 |
| Lilly USA, LLC | 3 | $55 |
| Dexcom, Inc. | 2 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $33 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Boston Scientific Corporation | 1 | $22 |
Products named: LEQVIO, Veozah, TRELEGY ELLIPTA, JARDIANCE, QULIPTA, MOUNJARO, Dexcom G6 Transmitter, OTEZLA.
Industry payments across MO — which companies pay providers there.
